The Green Market Report hosted its first conference on Psychedelic Investing in New York City on January 24. This panel was titled “Business Strategy For Psychedelic Companies.

Journalist Jeremy Berke of Business Insider moderated this panel featuring Atai Life Sciences, which is a global biotech company that was created to address those suffering from mental health disorders. It has created a portfolio including Compass Pathways which uses Psilocybin as its lead compound. The company’s CEO Florian Brand will talk about how they have chosen the companies they have added to their platform and the promising uses of these innovative treatments. He is joined by Shlomi Raz, the founder of Eleusis, a clinical-stage life science company dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity and Dr. Terry Kelly, the CEO of Perception Neurosciences. Thank you for watching the Green Market Report! Subscribe to our channel – it’s Free!